|View printer-friendly version|
|April 02, 2006 1:35 p.m.|
|Teva Announces Approval of Deferoxamine Mesylate for Injection Usp|
Jerusalem, Israel, April 2, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval for the Company's ANDA for Deferoxamine Mesylate for Injection USP, 500 mg/vial and 2 g/vial. Shipment of this product will begin immediately.